The aim of this trial is to determine whether flumazenil can be given effectively and safely to patients with reduced consciousness following suspected benzodiazepine overdose. Image Chief Investigator: Professor Michael Eddleston Number and location of participating sites (by region/ country): UK 5 sites ISRCTN number: 14373275 Funder: Medical Research Council (MRC) DPFS Start and End date Of grant award: 01 Feb 2024 – 31 Jul 2028 Of recruitment: 01 Oct 2024 - 31 May 2025 (Stage 1) 01 Dec 2025 - 30 Jun 2026 (Stage 2) 01 Jan 2027 – 31 Jan 2028 (Stage 3) Current Status: In set up Trial Website: n/a Email: rufus.trial@ed.ac.uk UK GDPR Privacy Statement: Within patient information booklet Sponsor: ACCORD https://www.accord.ed.ac.uk/ Chief Investigator: Professor Michael Eddleston, Centre for Cardiovascular Science, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh BioQuarter, Edinburgh, EH16 4TJ m.eddleston@ed.ac.uk Trial Manager: Dr Laura Forsyth, Edinburgh Clinical Trials Unit, Usher Building, The University of Edinburgh, 5‒7 Little France Road, Edinburgh BioQuarter ‒ Gate 3 EDINBURGH EH16 4UX rufus.trial@ed.ac.uk ECTU involvement: Trial Management, Database and randomisation service provision This article was published on 2024-09-24
